Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic
News Jan 19, 2009
Rosetta Genomics Ltd. and collaborators have unveiled initial data relating to the company's colorectal cancer screening diagnostics test, miRscreen™ colon, which is based on a simple blood draw, and is expected to be released next year.
The company's scientists and collaborators have identified microRNA biomarkers in serum, which have the potential to accurately differentiate colorectal cancer patients from healthy individuals. The data is being presented at the ASCO 2009 Gastrointestinal Cancers Symposium, in San Francisco.
"The initial data presented by Rosetta is very significant" said Aaron Ciechanover, Nobel laureate and chairman of Rosetta's scientific advisory board. "Rosetta's scientists and their collaborators, have for the first time, identified in serum, potential microRNA biomarkers of colorectal cancer. If treated early, 90% of colon cancer patients survive. The humane, medical, and financial impact of an effective, non-invasive colon cancer screening test can not be overstated."
The company, together with collaborators, has shown that two microRNA biomarkers, obtained from a simple blood draw, identified colon cancer patients from healthy individuals with 91% sensitivity and 72% specificity.
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.